ID: ALA4088022

Max Phase: Preclinical

Molecular Formula: C21H14N4

Molecular Weight: 322.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#Cc1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1

Standard InChI:  InChI=1S/C21H14N4/c22-14-15-10-12-17(13-11-15)23-21-18-8-4-5-9-19(18)24-20(25-21)16-6-2-1-3-7-16/h1-13H,(H,23,24,25)

Standard InChI Key:  IHEBYSXJXPXZKN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 322.37

Molecular Weight (Monoisotopic): 322.1218

AlogP: 4.91

#Rotatable Bonds: 3

Polar Surface Area: 61.60

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.99

CX Basic pKa: 4.19

CX LogP: 5.57

CX LogD: 5.57

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.58

Np Likeness Score: -1.67

References

1. Krapf MK, Gallus J, Wiese M..  (2017)  4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).,  60  (10): [PMID:28471656] [10.1021/acs.jmedchem.7b00441]

2. Krapf MK, Gallus J, Vahdati S, Wiese M..  (2018)  New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.,  61  (8): [PMID:29547272] [10.1021/acs.jmedchem.7b01012]

3. Krapf MK, Wiese M..  (2016)  Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).,  59  (11): [PMID:27148793] [10.1021/acs.jmedchem.6b00330]

4. He ZX, Zhao TQ, Gong YP, Zhang X, Ma LY, Liu HM..  (2020)  Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters.,  200  [PMID:32497962] [10.1016/j.ejmech.2020.112458]

Source

Source(1):

• Scientific Literature